People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ocelot Bio, Inc. | — | Pharmaceuticals | Series B | $39.0M | $31.0M | 2023 |
Jennifer Schranz at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jennifer Schranz on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jack Nielsen | 1 | 13 |
| Camille Samuels | 1 | 6 |
| Geoffrey Harris | 1 | 4 |
| Donald Santel | 1 | 4 |
| Katherine Stultz | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.